The NAGA Group AG: Growth path continues, record transactions and volumes in the current Q4. Hauck & Aufhäuser starts coverage and gives NAGA a 'BUY' rating and a target price of EUR 5.90.
10.12.2020 14:53:00 EET | Business Wire | Press release
The NAGA GROUP (XETRA: N4G, ISIN: DE000A161NR7), provider of the social network for financial market trading NAGA.com, reports sustained growth at a high level in the months of October and November on its digital trading platform NAGA.com.
The number of real money transactions is at a record level. With a total of 1.3 million transactions and new monthly records in October with 645,000 and November with 680,000 the Q4 figure will clearly surpass the record of Q3 2020 (1.5 million transactions). At the same time, the trading volume in the current fourth quarter has already exceeded EUR 25 billion (Q3 2020: EUR 33 billion) and will therefore also reach a record level.
"We are fully on track to achieve our annual targets. We are pleased that our investments in Marketing & Sales are bearing fruits and that we can continue to expand and improve our customer base, customer activity and the entire platform. NAGA has found a growth formula that enables it to grow in a precise way, fully, digitally and on a global level. The market potential is promising and the industry is growing - especially due to accelerated digitization, the topic of investing is more popular than ever", summarizes the CEO Benjamin Bilski.
NAGA GROUP AG also announces that the analysts from Hauck & Aufhäuser Research have started coverage of The NAGA GROUP share. Analyst Frederik Jarchow gives a buy recommendation with a price target of EUR 5.90. This corresponds to an upside potential of around 80%. In the initial study, Hauck & Aufhäuser particularly highlights the successful global rollout and digital marketing strategy and underlines the unique symbiosis of a trading and social media platform, which should lead to high YoY sales growth in the coming years and an increasing EBITDA margin.
The full research study is available for download on the website at www.ir.naga.com in the "Publications" section.
Bilski comments on the initial coverage: "We are delighted that Hauck & Aufhäuser Research started covering our share. It is one of the most renowned sources of information at hand which provides as objective as possible an assessment of our growth potential. The FinTech market is growing rapidly and the NAGA GROUP has all the characteristics to grow with it. It also confirms that we want to increase the transparency of our company and deal more intensively with investor relations. We are pleased that we can point out the future opportunities of the NAGA GROUP to other private and institutional investors on a wider scale."
NAGA GROUP also reports on the successful launch of the neo banking app NAGA Pay. The mobile digital bank and the card program recorded over 6,000 users and over EUR 2.5 million in transaction volume in the first 21 days after launch. The app offers users a free IBAN account as well as a Mastercard and a crypto wallet using fully digital onboarding. Shortly before Christmas, the stock trading feature will be released within the app. At the beginning of the year 2021, NAGA will officially start the promotion of the app.
###
About NAGA
NAGA is an innovative fintech company that has developed a socially enhanced financial system that creates a unified and seamless experience across personal finance and investing. Its proprietary platform offers a range of products ranging from trading, investing, and cryptocurrencies to a physical Mastercard and social investing features such as a Feed, a Messenger and Auto-Copy. NAGA is a synergistic all-in-one solution that's accessible and inclusive, and that provides a better way to trade, invest, connect, earn, acquire and pay, across both fiat and crypto.
| Language: | English |
| Company: | The NAGA Group AG |
| Hohe Bleichen 12 | |
| 20354 Hamburg | |
| Germany | |
| E-mail: | info@naga.com |
| Internet: | www.naga.com |
| ISIN: | DE000A161NR7 |
| WKN: | A161NR |
| Indices: | Scale 30 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005476/en/
Contact information
Benjamin Bilski
Tel:+49-(0)40-5247-79153
Email:ben@naga.com
ingo.janssen@ubj.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 13:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reliability, operational efficiency and sustainability performance. The partnership brings together LTTS’ expertise in forward looking technologies and extensive experience ac
Faire Marks Five Years of Growth Outside North America: Over 100,000 Retailers, 50,000 Brands, and More Than One in Four Brands Now Selling Across Borders11.6.2026 12:05:00 EEST | Press release
Five years after launching outside North America, Faire’s community of more than 100,000 retailers and 50,000 brands across 30+ countries in Europe, Australia, and New Zealand shows a retail sector that is innovating and thriving, well beyond the big cities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611115823/en/ Faire Celebrates 5 Years of Growth in Europe "It has been a phenomenal five years for Faire internationally, and the opportunity ahead has never been clearer,” said Olivier Buffon, VP and Head of International at Faire. “Europe represents a retail market comparable in scale to North America, and the challenges Faire was built to solve exist wherever independent retail exists. A global platform is more valuable for everyone, and we’re so proud to support businesses becoming more confident and more global in how they buy and sell.” A Retailer Network Spanning Tens of Thousands of Towns Independent retail is al
Stallergenes Greer Will Present New Evidence on Long-term Outcomes in Allergen Immunotherapy at EAACI 202611.6.2026 11:09:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, will present new clinical evidence and scientific advances in allergen immunotherapy (AIT) at the European Academy of Allergy and Clinical Immunology (EAACI) congress, taking place from June 12 to 15 in Istanbul, Turkey. The company will host a scientific symposium entitled “From Nobel Prize discovery to AIT clinical evidence: Shaping pathways to respiratory allergy remission.”Three leading international experts will explore how landmark breakthroughs in immunology have deepened our understanding of immune tolerance, presenting emerging data on remission and long-term outcomes in respiratory allergy. Together, these insights reinforce AIT’s disease-modifying potential and its growing role in personalised medicine. “EAACI 2026 is an exceptional forum for the global allergy community to exchange knowledge and advance the field. Stallergenes Greer is proud contribute to these conversations, bringing together world-leading experts in pur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom